Fractyl Health, Inc. Financing Cash Flow
Fractyl Health, Inc. (GUTS) reported Financing Cash Flow of $3.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Fractyl Health, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$127.00K, a 108.58% decline year-over-year.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.11M, a 2300.58% increase year-over-year.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $25.22M, a 37544.78% increase year-over-year.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $78.09M, a 48102.47% increase year-over-year.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $104.96M, a 3.69% increase from fiscal 2024.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $101.23M, a 268.94% increase from fiscal 2023.
- Fractyl Health, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $27.44M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.98M 10-Q · filed 2026-08-10 | $29.20M derived: sum of 3 quarters · filed 2026-08-10 | $107.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.11M 10-Q · filed 2026-05-12 | $29.33M derived: sum of 2 quarters · filed 2026-05-12 | $107.42M derived: sum of 3 quarters · filed 2026-05-12 | $108.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $25.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $103.31M derived: sum of 2 quarters · filed 2026-03-24 | $104.79M derived: sum of 3 quarters · filed 2026-08-10 | $104.96M 10-K · filed 2026-03-24 |
| 2025-09-30 | $78.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $79.57M derived: sum of 2 quarters · filed 2026-08-10 | $79.74M 10-Q · filed 2025-11-12 | $79.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.65M 10-Q · filed 2026-08-10 | $1.72M derived: sum of 3 quarters · filed 2026-08-10 | $1.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $171.00K 10-Q · filed 2026-05-12 | $238.00K derived: sum of 2 quarters · filed 2026-05-12 | $400.00K derived: sum of 3 quarters · filed 2026-05-12 | $395.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $229.00K derived: sum of 2 quarters · filed 2026-03-24 | $224.00K derived: sum of 3 quarters · filed 2026-03-24 | $101.23M 10-K · filed 2026-03-24 |
| 2024-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $157.00K derived: sum of 2 quarters · filed 2025-11-12 | $101.16M 10-Q · filed 2025-11-12 | $100.60M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $101.00M 10-Q · filed 2025-08-12 | $100.44M derived: sum of 3 quarters · filed 2025-08-12 | $128.41M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $101.00M 10-Q · filed 2025-05-13 | $100.45M derived: sum of 2 quarters · filed 2025-05-13 | $128.41M derived: sum of 3 quarters · filed 2025-05-13 | $128.44M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $27.41M derived: sum of 2 quarters · filed 2025-03-03 | $27.44M derived: sum of 3 quarters · filed 2025-03-03 | $27.44M 10-K · filed 2025-03-03 |
| 2023-09-30 | $27.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $28.00M derived: sum of 2 quarters · filed 2024-11-12 | $27.99M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $26.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$2.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |